TEI 9826

Drug Profile

TEI 9826

Alternative Names: Free acid of TOK 4528; Lipo-TEI 9826

Latest Information Update: 19 Oct 2000

Price : $50

At a glance

  • Originator Teijin Pharma
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 19 Oct 2000 Discontinued-Preclinical for Cancer in Japan (Unknown route)
  • 20 Jun 2000 A preclinical study has been added to the adverse events, pharmacokinetics and Cancer pharmacodynamics sections
  • 24 Feb 2000 A preclinical study has been added to the pharmacokinetics and Cancer pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top